Covid-19

#Biopharmaceuticals #Covid-19

IDWeek 2021 will showcase scientific progress in infectious diseases

AstraZeneca will present data across its Covid-19 and respiratory syncytial virus (RSV) pipeline as three late-breaking oral presentations at the 10th Annual IDWeek Virtual Conference, September 29 to October 3, 2021, illustrating its commitment to advancing innovative science in infectious diseases.  The presentations include AZD7442 long-acting antibody combination… Read More

#News

#Awards #Covid-19 #Immunology / Virology & Vaccines

NIAID issues new awards to fund “pan-coronavirus” vaccines  

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded approximately $36.3 million to three academic institutions to conduct research to develop vaccines to protect against multiple types of coronaviruses and viral variants. The awards are intended to fuel vaccine… Read More

#News

#Antibodies #Covid-19 #Drug discovery #Drug therapy #Infographic #Monoclonal antibodies #Research

Study illuminates surfaces of spike most resistant to antibody escape 

Scientists at La Jolla Institute for Immunology (LJI) have published a detailed map of where human antibodies bind to SARS-CoV-2, which was generated by a global collaboration comparing nearly all leading clinical candidates. The new research, published in Science, will guide the development of more effective Covid-19 antibody… Read More

#Covid-19 #News

#Clinical trials #Covid-19 #Funding

iiCON secures over £150 million investment and creates 176 jobs   

The Infection Innovation Consortium (iiCON) is a global centre for infectious disease R&D and created 176 high-value jobs in the North West of the UK.   The consortium has raised £154.9 million in public and private investment in its first year – creating a £173.5 million programme. … Read More

#News

#Biopharmaceuticals #Covid-19 #GlobalData

Covid-19 shapes Indian pharma deals landscape

India has a rapidly growing pharmaceutical market that, being the third largest pharmaceutical industry in the world by volume, holds a prominent place in global health. Over the last decade, the Indian pharmaceutical market has seen increasing domestic and foreign investment. While the overall number of deals fluctuated only slightly… Read More

#Covid-19 #News #Trends & Analysis

#Covid-19 #GlobalData #Immunology / Virology & Vaccines #mRNA

Too many US adults unvaccinated to vaccinate children 

Following the news that Pfizer/BioNTech will apply for authorisation of their Covid-19 vaccine Comirnaty for children ages 5–11 after showing positive initial data from a trial at a lower dose in this age group; Philipp Rosenbaum, Senior Healthcare Analyst at GlobalData, offers his view.   He said: “It will be… Read More

#Covid-19 #News #Trends & Analysis

#AstraZeneca #Covid-19 #Immunology / Virology & Vaccines #Moderna #Pfizer

Health Canada approves Moderna, Pfizer and AstraZeneca vaccines 

Health Canada has approved Moderna’s New Drug Submission (NDS-CV) for Spikevax (elasomeran mRNA vaccine), it has granted full approval (Notice of Compliance or NOC) for Pfizer’s Comirnaty, and it has approved the AstraZeneca vaccine, which will be named Vaxzevria.  “Health Canada’s approval of our Covid-19 vaccine is an important milestone as it is our… Read More

#Covid-19 #News #Regulatory

#Cancer immunotherapy #Cancer research #Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Can Covid-19 vaccine technology be used for cancer vaccines?

Scientists from the University of Oxford and the Ludwig Institute for Cancer Research are building on the Oxford-AstraZeneca vaccine for SARS-CoV-2 to develop a vaccine to treat cancer.   Researchers have designed a two-dose therapeutic cancer vaccine using Oxford’s viral vector vaccine technology. When tested in mouse tumour models, the… Read More

#Cancer Research #Covid-19 #Editor's Choice #News

#Clinical trials #Collaboration #Covid-19 #Immunology / Virology & Vaccines #Pharmaceutical #Research

Early trial of first multivariant Covid-19 vaccine booster begins

A Phase I clinical trial of the world’s first multivariant Covid-19 vaccine has been launched by US pharmaceutical company Gritstone in collaboration with The University of Manchester UK and Manchester University NHS Foundation Trust.  Initially involving participants aged 60+, its creators say the drug, GRT-R910, can boost… Read More

#News

#Clinical trial #Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA #Research

Moderna: new clinical data on its Covid-19 vaccine 

New analysis suggests that the Moderna Covid-19 vaccine is highly effective against circulating variants of concern, including in a vaccine effectiveness study conducted in partnership with Kaiser Permanente Southern California (KPSC) and in a separate recent publication by the US Centers for Disease Control and Prevention (CDC).   Additionally, the company shared… Read More

#Covid-19 #News #Trending News

#Biomarkers #Clinical trials #Covid-19 #Pharma #Pneumonia #Research

Ruconest-treated patients test lower disease severity scores for Covid-19 

Pharming Group has announced the topline results from two randomised, open label, controlled, pilot clinical trials of patients hospitalised with Covid-19 treated with Ruconest (recombinant human C1 inhibitor) for the prevention of severe SARS-CoV-2 infection. The primary endpoint in both studies was disease severity on the seven-point WHO ordinal scale on Day Seven. … Read More

#News

Covid-19
#Clinical trials #Covid-19 #Drug development #Oncology #Therapeutics

Oncology treatment tested in patients with moderate Covid-19 disease 

Australian clinical-stage drug development company Noxopharm has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil (Veyonda), a TBK1 (TANK-binding kinase 1) inhibitor, as an anti-inflammatory in patients with moderate Covid-19 disease. Veyonda currently has two main drug actions – a moderating… Read More

#Covid-19 #News #Trending News

#Covid-19 #FDA #In vitro

FDA-approved drugs reduced SARS-CoV-2 infection in lab 

An in vitro study of drugs already approved by the US Food and Drug Administration (FDA) to treat a range of conditions has shown eight of them are also effective in slowing SARS-CoV-2 replication in infected human cells. The team led by University of Manchester scientists used the drugs… Read More

#News

#Collaboration #Covid-19 #Therapeutics

Exscientia and Gates Foundation’s antiviral therapeutics  

Exscientia has entered a four-year collaboration with the Bill & Melinda Gates Foundation to develop small molecule therapeutics that tackle the current coronavirus pandemic and help prepare for future pandemics.   The collaboration will initially focus on developing broad-spectrum coronavirus agents (e.g., SARS-CoV-2 and its variants, MERS), including accelerating Exscientia’s lead programme,… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines #Podcast #Research

Putting virology back on the map: podcast 

This is the latest episode of the free DDW podcast, “Putting virology back on the map: the fight against Covid-19”. It covers two articles written for Volume 22, Issue 1 – Winter 2020/21 of the Drug Discovery World Magazine.   The first article is a case study titled… Read More

#News